Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for Hypoglycemia

 

Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program

https://www.globenewswire.com/news-release/2024/12/03/2990549/0/en/FDA-Grants-Orphan-Drug-Designation-to-Rezolute-s-Ersodetug-RZ358-for-the-Treatment-of-Hypoglycemia-Due-to-Tumor-Hyperinsulinism.html